We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Unveiling Teladoc (TDOC) Q3 Outlook: Wall Street Estimates for Key Metrics
Read MoreHide Full Article
The upcoming report from Teladoc (TDOC - Free Report) is expected to reveal quarterly loss of -$0.23 per share, indicating a decline of 9.5% compared to the year-ago period. Analysts forecast revenues of $585.55 million, representing a decline of 6.5% year over year.
Over the past 30 days, the consensus EPS estimate for the quarter has remained unchanged. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.
Prior to a company's earnings announcement, it is crucial to consider revisions to earnings estimates. This serves as a significant indicator for predicting potential investor actions regarding the stock. Empirical research has consistently demonstrated a robust correlation between trends in earnings estimate revision and the short-term price performance of a stock.
While investors typically rely on consensus earnings and revenue estimates to gauge how the business may have fared during the quarter, examining analysts' projections for some of the company's key metrics often helps gain a deeper insight.
With that in mind, let's delve into the average projections of some Teladoc metrics that are commonly tracked and projected by analysts on Wall Street.
The combined assessment of analysts suggests that 'Revenues by Segment- Integrated Care' will likely reach $394.98 million. The estimate indicates a year-over-year change of +1.4%.
It is projected by analysts that the 'Revenues by Segment- BetterHelp' will reach $192.32 million. The estimate indicates a change of -18.8% from the prior-year quarter.
Analysts expect 'U.S. Integrated Care Members' to come in at 99.76 million. Compared to the current estimate, the company reported 102.50 million in the same quarter of the previous year.
The consensus among analysts is that 'Adjusted EBITDA- BetterHelp' will reach $1.67 million. The estimate is in contrast to the year-ago figure of $3.84 million.
The average prediction of analysts places 'Adjusted EBITDA- Integrated Care' at $63.49 million. The estimate compares to the year-ago value of $66.07 million.
Over the past month, shares of Teladoc have returned +5.9% versus the Zacks S&P 500 composite's -0.8% change. Currently, TDOC carries a Zacks Rank #3 (Hold), suggesting that its performance may align with the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
View the Zacks #1 Rank List
Image: Bigstock
Unveiling Teladoc (TDOC) Q3 Outlook: Wall Street Estimates for Key Metrics
The upcoming report from Teladoc (TDOC - Free Report) is expected to reveal quarterly loss of -$0.23 per share, indicating a decline of 9.5% compared to the year-ago period. Analysts forecast revenues of $585.55 million, representing a decline of 6.5% year over year.
Over the past 30 days, the consensus EPS estimate for the quarter has remained unchanged. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.
Prior to a company's earnings announcement, it is crucial to consider revisions to earnings estimates. This serves as a significant indicator for predicting potential investor actions regarding the stock. Empirical research has consistently demonstrated a robust correlation between trends in earnings estimate revision and the short-term price performance of a stock.
While investors typically rely on consensus earnings and revenue estimates to gauge how the business may have fared during the quarter, examining analysts' projections for some of the company's key metrics often helps gain a deeper insight.
With that in mind, let's delve into the average projections of some Teladoc metrics that are commonly tracked and projected by analysts on Wall Street.
The combined assessment of analysts suggests that 'Revenues by Segment- Integrated Care' will likely reach $394.98 million. The estimate indicates a year-over-year change of +1.4%.
It is projected by analysts that the 'Revenues by Segment- BetterHelp' will reach $192.32 million. The estimate indicates a change of -18.8% from the prior-year quarter.
Analysts expect 'U.S. Integrated Care Members' to come in at 99.76 million. Compared to the current estimate, the company reported 102.50 million in the same quarter of the previous year.
The consensus among analysts is that 'Adjusted EBITDA- BetterHelp' will reach $1.67 million. The estimate is in contrast to the year-ago figure of $3.84 million.
The average prediction of analysts places 'Adjusted EBITDA- Integrated Care' at $63.49 million. The estimate compares to the year-ago value of $66.07 million.
View all Key Company Metrics for Teladoc here>>>Over the past month, shares of Teladoc have returned +5.9% versus the Zacks S&P 500 composite's -0.8% change. Currently, TDOC carries a Zacks Rank #3 (Hold), suggesting that its performance may align with the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .